Wuhan Hiteck Biological Pharma Co.,Ltd

300683

CNE1000034C5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 12/05/2024 BST			5-day change	1st Jan Change
24.81 ^CNY	-4.39%		-0.80%	-31.29%

04-21	Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
02-20	Wuhan Hiteck Biological Pharma Co.,Ltd completed the acquisition of a 6.995% stake in Beijing Shadong Biotechnology Co., Ltd. from JunHe Enterprise Management Co., Ltd., Yang Shifang, Cui Junsheng, Sha Bingdong and Guo Cheng	CI

Wuhan Hiteck Biological Pharma Co., Ltd. Announces Executive Changes

January 25, 2021 at 07:32 pm

Wuhan Hiteck Biological Pharma Co., Ltd. held its 1st Extraordinary General Meeting of 2021 on 22 January 2021, during which the following proposal(s) was/were approved: 1. Change of directors 1. Hou Pengyi. Change of independent directors, Ran Mingdong and Li Wenxin.

Latest news about Wuhan Hiteck Biological Pharma Co.,Ltd

Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-21	CI
Wuhan Hiteck Biological Pharma Co.,Ltd completed the acquisition of a 6.995% stake in Beijing Shadong Biotechnology Co., Ltd. from JunHe Enterprise Management Co., Ltd., Yang Shifang, Cui Junsheng, Sha Bingdong and Guo Cheng	02-19	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23	CI
Hiteck Biological Pharma Gets Nod to Trial Eye Drops	09/10/23	MT
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	30/08/23	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	24/04/23	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	24/04/23	CI
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it has received CNY 294.999985 million in funding from Nuode Asset Management Co., Ltd., Caitong Fund Management Co., Ltd., Shanghai Boshen Investment Center (Limited Partnership), Shenzhen Qianhai Eagle Fund Management Co., Ltd., UBS Group AG, Guodu Venture Capital Co., Ltd., and other investors	01/02/23	CI
Hiteck Biological Pharma Gets Regulatory Consent for Share Sale	23/01/23	MT
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	24/10/22	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	02/08/22	CI
Wuhan Hiteck Biological Pharma Co.,Ltd announced that it expects to receive CNY 300 million in funding	17/05/22	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22/04/22	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22/04/22	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Approves Board Appointments	13/12/21	CI
Wuhan Hiteck Biological Pharma Co.,Ltd agreed to acquire additional 6.9416% stake in Beijing Shadong Biotechnology Co., Ltd. from Beijing Zhongguancun VC Development Co., Ltd.	14/11/21	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	28/10/21	CI
Wuhan Hiteck Biological Pharma : Bio-Pharma Nets $91 Million From Private Placement	15/10/21	MT
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	25/08/21	CI
Wuhan Hiteck Biological Pharma Co., Ltd. announced that it has received CNY 599.972 million in funding from a group of investors	03/08/21	CI
Xiweiai Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Wuhan Hiteck Biological Pharma Co.,Ltd	20/07/21	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	22/04/21	CI
Wuhan Hiteck Biological Pharma Co., Ltd. Announces Executive Changes	25/01/21	CI
Wuhan Hiteck Biological Pharma Co.,Ltd intends to acquire a 67% stake in Xiamen Weijia Pharmaceutical Co., Ltd. from Yongxin County Xinxinyuan Enterprise Management Consulting Center (Limited Partnership) for CNY 70.01 million.	12/11/20	CI
Wuhan Hiteck Biological Pharma Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2020	26/10/20	CI

Chart Wuhan Hiteck Biological Pharma Co.,Ltd

Duration

Period

Chart Wuhan Hiteck Biological Pharma Co.,Ltd

More charts

Company Profile

Wuhan Hiteck Biological Pharma Co Ltd is a biopharmaceutical company. The Company operates five segments. The Biopharmaceutical segment is engaged in research, development, production and sales of biological products, and its primary product is mouse nerve growth factor for injection named Jinlujie. The Medical Technology Service segment is mainly involved in the technical development, technical consultation and technology transfer of chemical drugs. The In Vitro Diagnostic Reagents segment operates the research, development, production and sales of in vitro diagnostic reagents. The Pharmaceutical Sales and Wholesale segment is engaged in the sales and wholesale of pharmaceuticals. The Other segmentâs businesses include the cultivation and sales of Chinese herbal medicines, and the wholesale and retail of health products.

Sector

Pharmaceuticals

Calendar

16/05/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
WUHAN HITECK BIOLOGICAL PHARMA CO.,LTD	-31.29%	470M
ELI LILLY AND COMPANY	+29.14%	684B
NOVO NORDISK A/S	+30.34%	568B
JOHNSON & JOHNSON	-3.91%	361B
MERCK & CO., INC.	+17.55%	329B
ABBVIE INC.	+4.53%	284B
ASTRAZENECA PLC	+16.21%	240B
NOVARTIS AG	+9.66%	208B
ROCHE HOLDING AG	-6.83%	200B
AMGEN INC.	+7.51%	166B

Other Pharmaceuticals